Calendario›ONC›BG-89894

BG-89894

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Ensayo de BeOne Medicines Ltd. en Advanced or Metastatic MTAP-deleted Solid Tumors (del registro, en inglés).

Fase

Fase 1

Estado

Interrumpido

Participantes

29

previstos

Centros

20

Fin del objetivo primario

abr 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2024.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «The study was discontinued following an internal decision by the sponsor».

Qué mide

Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (From first dose of the study drug to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first (approximately 18 months)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.

Más ensayos de ONC

Todos los de ONC, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06568614), actualizada en may 2026.